Pharmaceuticals

Pharmalot Ed Silverman

STAT Plus: Colorado board decides a pricey Novartis medicine is unaffordable

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more

Biotech Sarah Owermohle, Allison DeAngelis, and Adam Feuerstein

STAT Plus: Biopharma execs cheer Supreme Court for upholding FDA authority in abortion pill case

The Readout Meghana Keshavan

With Avidity and Pfizer, gene therapy enters a phase

Pharma Andrew Joseph

STAT Plus: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried

The Readout Elaine Chen

STAT Plus: What do Parkinson’s and obesity have in common?

Video Anna Yeo

STAT Plus: Watch: How pharmacy benefit managers influence drug pricing

Video Anna Yeo

STAT Plus: Watch: The role of PBMs, patents, and public health in drug pricing

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices

The Readout Elaine Chen

Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know

The Readout Meghana Keshavan

The biotech news you missed from the weekend

Health Helen Branswell

STAT Plus: FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults

The Readout Meghana Keshavan

STAT Plus: Vanda Pharmaceuticals has another suitor

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

First Opinion Jayasree K. Iyer

Obesity drugs pose a big challenge for health care equity

Biotech Jonathan Wosen and Meghana Keshavan

STAT Plus: At BIO, signs Congress’ tough stance on China is chilling biotech relationships

The Readout Elaine Chen

Novavax will be able to supply Covid-19 vaccines this fall

Health Annalisa Merelli

Withdrawal symptoms hit one in six patients stopping antidepressants, review finds

The Readout Jason Mast

STAT Plus: Testing begins for a new form of PrEP

Pharmalot Ed Silverman

STAT Plus: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits

Biotech Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care

Politics Sarah Owermohle

STAT Plus: Senators tussle over abortion policy against the backdrop of a presidential campaign

Pharmalot Ed Silverman

STAT Plus: U.S. drug shortages have reached a decade high and are lasting longer, too

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

Biotech Angus Chen

STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Pharma Andrew Joseph

STAT Plus: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market

Pharma Adam Feuerstein, Matthew Herper, and Angus Chen

STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug